

1 **Title: Assessing Neuropsychiatric Symptoms in Long COVID: A Retrospective Cohort Study**  
2 **from a South Texas Long COVID Clinic**

3 **Authors:** Anne Marie Wells, MS<sup>1,2</sup>; Summer Rolin, PsyD<sup>3,6</sup>; Barbara Robles-Ramamurthy, MD<sup>6</sup>;  
4 Gabriela Gibson-Lopez, PsyD<sup>4,6</sup>; Martin Goros, MS<sup>7</sup>; Jonathan A Gelfond, MD, PhD<sup>7</sup>; Stephen Gelfond,  
5 MD<sup>6</sup>; Philip Balfanz, MD, MBA<sup>6</sup>; Melissa Deuter, MD<sup>6</sup>; Donald McGeary, PhD<sup>5,6</sup>; Monica Verduzco-  
6 Gutierrez, MD<sup>3,6</sup>

7  
8 **Affiliations:**

- 9 1. South Texas Medical Scientist Training Program, UT Health San Antonio, San Antonio, TX, USA  
10 2. Department of Pharmacology, UT Health San Antonio, San Antonio, TX, USA  
11 3. Department of Rehabilitation Medicine, UT Health San Antonio, TX, USA  
12 4. Department of Family & Community Medicine, UT Health San Antonio, San Antonio, TX, USA  
13 5. Department of Psychiatry & Behavioral Health Sciences, UT Health San Antonio, San Antonio,  
14 TX, USA  
15 6. South Texas Psychiatry Practice-Based Research Network (PBRN), San Antonio, TX, USA  
16 7. Department of Population Health Sciences, UT Health San Antonio, San Antonio, TX, USA  
17

18  
19  
20 **Corresponding Author:**

21 Verduzco-Gutierrez; 7703 Floyd Curl Dr., Mail Code 7798, San Antonio, TX 78209  
22

23 **Key Words:** PASC, Long COVID, PTSD, stress, depression, anxiety, PCL-5, GAD-7, PHQ-9  
24

25 **Tables:** 3

26 **Figures:** 4

27 **Supplement:** Figures (2), Tables (1)  
28

29 **Author Contributions**

30 SR, MVG, BRR, GGL, PB, MD, AMW and SG conceived the project, generated hypotheses, and supplied  
31 patient records for data collection. SR completed the application for IRB approval. JG, MG, SR, MVG,  
32 BRR, and AMW performed the data analysis. AMW wrote the manuscript. SR, MVG, AMW, JG, and DM  
33 revised and edited the manuscript. All authors reviewed and approved the final manuscript for submission.  
34

35 **Acknowledgements**

36 This was a study completed by the interdisciplinary collaborations of the South Texas Psychiatry Practice-  
37 Based Research Network (PBRN). We would like to express our gratitude to the patients who entrusted  
38 our team with the data for this study. Our also extend our sincere gratitude to the many students who  
39 performed data collection and contributed to the development of poster presentations of this study (Anne  
40 Marie Wells, Richa Sinkre, Ashley Chakales, Sean Rumney, and Phillip Yang). Finally, we thank the  
41 South Texas Psychiatry PBRN staff, especially Kaitlyn Waxler, for their persistence and keeping the study  
42 organized.  
43

44 **Funding**

45 The project described was supported by the National Center for Advancing Translational Sciences,  
46 National Institutes of Health, through Grants UM1 TR004538 (JAG, MG). Training for AMW was  
47 supported by F30MH134482, T32R004545, STX-MSTP (T32GM113896 / T32GM145432), T32NS082145,  
48 R25NS089462. The content is solely the responsibility of the authors and does not necessarily represent  
49 the official views of the NIH.  
50

51  
52  
53  
54 **Compliance with Ethical Standards**

55 The authors have no disclosures.  
56

57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68

69 **Abstract**

70 Long COVID, previously known as Post-Acute Sequelae of SARS-CoV-2 (PASC), refers to prolonged  
71 symptoms or diagnosable conditions following COVID-19 infection. The neuropsychiatric profile of Long  
72 COVID patients remains ambiguous. This study aimed to assess neuropsychiatric symptoms in a  
73 retrospective cohort of Long COVID patients (N = 162) at a Rehabilitation Medicine clinic in South Texas.  
74 Clinical data from patient records were used to calculate a Symptom Score, and screening tools for  
75 stress/PTSD (PCL-5), anxiety (GAD-7), and quality of life (SWL) were employed to evaluate if Long  
76 COVID duration and severity could predict neuropsychiatric outcomes. The majority were female (71%)  
77 and Hispanic (53%) who presented for treatment of Long COVID symptoms during the study period,  
78 including fatigue (93%), coughing/shortness of breath (81%), fever (67%), anosmia (58%), ageusia (54%),  
79 and weight loss (56%). There was a high burden of neuropsychiatric symptoms, including subjective  
80 cognitive impairment (79%), headache (74%), and insomnia (58%). Symptom Score (median = 9, IQR  
81 [8,11]) was significantly correlated with increased depression (PHQ-9;  $p < 0.05$ ), anxiety (GAD-7;  $p <$   
82  $0.05$ ) and elevated stress/PTSD (PCL-5;  $p < 0.05$ ) symptoms. Long COVID patients taking stimulants or  
83 mood stabilizers had higher GAD-7 ( $p < 0.031$ ,  $p < 0.035$ ) and PHQ-9 ( $p < 0.034$ ,  $p < 0.009$ ) scores but  
84 not PCL-5 scores. Importantly, duration of Long COVID symptomatology also did not predict PCL-5  
85 scores. No patient factors (e.g., sex, age, BMI, ethnicity) mediated Symptom Score. Nonetheless,  
86 historically marginalized groups, such as women and Hispanics, have been disproportionately affected by  
87 COVID-19. This study is the first to utilize validates screening tools to determine the presence and  
88 severity of neuropsychiatric symptoms in Long COVID patients. These findings may guide clinical  
89 management and future research on Long COVID, especially in historically excluded populations.

90  
91  
92

93 **Scope Statement**

94  
95 We enthusiastically submit our Original Research article, entitled “**Assessing Neuropsychiatric**  
96 **Symptoms in Long COVID: A Retrospective Cohort Study from a South Texas Long COVID Clinic**”  
97 for consideration for publication in the journal *Frontiers in Neurology*. We believe the scope of our article  
98 aligns well with the scope and aim of the journal’s *Neurorehabilitation Section*.  
99

100 Long COVID is a debilitating neurological disorder with prominent and enduring cognitive and  
101 psychological impact. This study sought to characterize Long COVID symptoms from a cohort of patients  
102 at a Rehabilitation Medicine/Long COVID clinic in Southwest Texas. We stratified symptoms using  
103 validated psychiatric evaluation tools (e.g., PCL-5, GAD-7, PHQ-9) to determine if and to what extent  
104 psychiatric comorbidity exacerbated Long COVID symptoms. Our findings suggest that a Long COVID  
105 patient’s depression, anxiety, and stress/post traumatic stress scores are highly correlated with other  
106 neurological symptoms. We advance the implementation of a Long COVID “Symptom Score”, as well as  
107 the use of validated screening instruments to identify psychiatric features of Long COVID with the goal of  
108 maximizing life satisfaction and function over the course of treatment.  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124

## 125 Introduction

126 The SARS-CoV-2 virus, which causes acute COVID-19 infection, is an ongoing public health concern that  
127 is here to stay (1). Therefore, continued study of this disease and its multifactorial impact on health and  
128 longevity is essential to advance the development of effective therapeutic and prevention strategies. Most  
129 individuals recover from COVID-19 infection within 5-20 days, depending on severity of symptoms;(2,3)  
130 yet a recent meta-analysis (4) estimated 31-69% of COVID-19 patients endure ongoing, relapsing and  
131 remitting, or progressive symptoms beyond 30 days of primary infection. The resulting syndrome is known  
132 as Post-Acute Sequelae of SARS-CoV-2 (PASC)(5) or Long COVID, which is now defined by the National  
133 Academy of Sciences, Engineering, and Medicine as an infection-associated chronic condition (IACC)  
134 that occurs after SARS-CoV-2 infection and is present for at least 3 months as a continuous, relapsing  
135 and remitting, or progressive disease state that affects one or more organ systems(6).  
136 Long COVID symptomatology (5,7–9) has been tracked in both small(10) and large(9,11,12) longitudinal  
137 cohort studies. In addition to continued symptoms of the acute infection (e.g., coughing, shortness of  
138 breath, loss of taste and smell), all studies to date have identified a common clustering of symptoms  
139 primarily affecting neurologic or neuropsychiatric systems(4,5,9–12). These symptoms include chronic  
140 fatigue, cognitive impairment (“brain fog”), headache, pain syndromes, anxiety and depression. Most  
141 patients experience Long COVID cluster symptoms for at least 6 months and upwards of 3 years out from  
142 primary infection(9). Thus, Long Covid poses a significant and chronic disruption to patient lives, as  
143 demonstrated by increased disability and economic burden reported in this population(13).  
144 Risk factors(9,13–15) for Long COVID include those for risk of more severe COVID-19 infection, such as  
145 obesity, age, premorbid metabolic or cardiovascular conditions -- and, critically, healthcare equity and  
146 access. Historically marginalized groups, like women and Hispanics, have been disproportionately  
147 impacted by the COVID-19 pandemic(13–18). Strikingly, the largest cohorts following the natural history  
148 of Long COVID have disproportionately sampled Caucasian men(9,11). Thus, there may be significant  
149 gaps in our understanding of how various patient factors may impact the complexity and duration of  
150 PASC symptoms. There are no cures nor adequate treatments for Long COVID apart from symptom  
151 management. Importantly, studies published to date have relied entirely on self-reported neuropsychiatric  
152 symptoms without the support of validated screening tools that could facilitate uncovering the etiology of  
153 neuropsychiatric symptoms.  
154 We hypothesized that while chronic stress and anxiety do not directly facilitate the development of Long  
155 COVID, they may contribute to its complex symptomatology. Thus, we sought to characterize Long  
156 COVID symptoms in a cohort of patients (N = 162; 71% female, 53% Hispanic, median BMI = 30 [obese])  
157 who presented in a Rehabilitation Medicine clinic in South Texas. We applied a proof-of-concept  
158 methodology to rapidly screen for major clusters of Long COVID symptomatology (i.e., “Symptom Score”)  
159 that can be employed with a battery of widely used screening tools for comorbid stress, anxiety, and  
160 mood disorder neuropsychiatric symptoms. Our findings point to high burden of fatigue, cognitive  
161 impairment, and anxiety measures in Long COVID patients that exacerbate the core Long COVID  
162 symptom profile. The associated impact on quality of life and risk of worsening psychiatric conditions  
163 demands greater attention to neuropsychiatric symptoms in the management of Long COVID patients,  
164 particularly amongst marginalized groups.

165

166

167

168

## 169 Results

### 170 *Long COVID patients report high rates of fatigue with neuropsychiatric symptomatology*

171 We characterized the self-reported symptom profile in Long COVID patients (N = 162), defined as  
172 symptoms or conditions present for at least 30 days after acute COVID-19 infection. Symptoms and  
173 conditions considered in this study were based on major categories determined by previous  
174 studies(5,9,11). The top-ranked symptoms within this cohort are summarized in Figure 1. Of note, 89% of  
175 the sample received an initial COVID-19 infection diagnosis by positive test (Fig 1). The distribution of  
176 approximate time elapsed since COVID-19 infection was approximately normal (Fig S1A). Of note, all  
177 patients received initial COVID-19 diagnosis within one of the major peaks of the COVID-19 pandemic  
178 (Fig S2).

179 The most common symptom reported in our cohort was fatigue (93%). At time of assessment, only 25%  
180 were currently exercising. Patients commonly reported myriad symptoms commonly associated with Long

181 COVID fatigue(19), such as gastrointestinal (diarrhea [43%]), nausea/vomiting [38%], weight loss [58%])  
182 and autoimmune (rash [21%]) symptoms. Most patients also reported a prolonged cluster of symptoms of  
183 acute COVID-19 infection, including coughing or shortness of breath (81%), fever (67%), loss of smell  
184 (58%), and loss of taste (54%).

185 The burden of neuropsychiatric symptoms in this cohort was striking. A substantial number of patients  
186 reported subjective cognitive impairment (79%), headache (74%), increased time spent in bed (73%),  
187 insomnia/sleep disturbance (58%). Many patients also reported new onset of muscle and/or joint pain  
188 (78%).

189 In this analysis, we noted that very few patients in this cohort reported being hospitalized or requiring a  
190 ventilator during initial COVID-19 infection. Moreover, few required oxygen therapy or sustained cardiac  
191 damage because of COVID-19 infection. Thus, our cohort largely represents a patient group with Long  
192 COVID symptomatology following non-severe primary COVID-19 infection.

#### 193 *Patient factors do not predict Long COVID Symptom Score*

194 We next sought to determine if patient factors predicted Long COVID symptom burden (Table 1). To this  
195 end, we ranked the incidences of self-reported symptoms or conditions present in our cohort. We then  
196 summed the total number of symptoms reported from the top 16-ranked symptoms for each patient as a  
197 Symptom Score. The median Symptom Score was 9 (IQR [8, 11]). We analyzed the relatedness of  
198 Symptom Scores across the cohort to patient factors. We also sought to determine if there were  
199 significant differences in patient factors between two subgroups divided by the median Symptom Score.  
200 We considered various patient factors, including biological sex, age, body mass index (BMI), race and  
201 ethnicity.

202 More female (N = 117, 73%) than male (N = 44, 27%) patients presented for evaluation for Long COVID  
203 symptoms during the study period. There was a higher proportion of females with above median symptom  
204 score compared to males, but this difference did not reach statistical significance (78% vs 68%,  $p = 0.2$ ).  
205 Thus, despite significantly more females in our sample, there was no contribution of biological sex to  
206 Symptom Score. Moreover, age (median= 44, IQR [35, 54]) and BMI (median = 30, IQR [26,36]) also  
207 failed to predict Symptom Score ( $p = 0.4, 0.7$ , respectively). Likely due to the geographic location of this  
208 study, most patients identified as Hispanic (53%). Yet, no race or ethnicity identified in this cohort were  
209 associated with Symptom Score ( $p = 0.8$ ).

#### 211 *Stress, anxiety, and satisfaction with life vary amongst Long COVID patients*

212 Given the high contribution of neuropsychiatric symptoms to Symptom Score and disease burden, we  
213 sought to determine if the additional psychiatric symptoms could predict Symptom Score. In a first, we  
214 administered validated screening tools to assess the presence and severity of stress rising to the level of  
215 post-traumatic stress disorder (PTSD; PCL-5), anxiety (GAD-7), depression (PHQ-9), and general  
216 satisfaction with life (SWL).

217 The categorical score results across these screening tools are summarized in Table 2. PCL-5 score  
218 revealed 44% of the sample lived with stress-related symptoms that rise to the level of PTSD. We were  
219 unable to analyze this finding considering the index (inciting) traumatic event, and thus cannot attribute  
220 symptoms to Long COVID symptoms or COVID-19 infection specifically. GAD-7 scores demonstrated  
221 69% of Long COVID patients demonstrated at least mild anxiety symptoms with 18% affected by severe  
222 anxiety. Most (74%) patients screened for depression with PHQ-9 had symptoms characterized by at  
223 least mild depression with 28% experiencing moderately severe to severe symptoms. Of note,  
224 approximately 41% of the cohort was slightly to extremely dissatisfied with life.

225 We then sought to determine if Symptom Score informed stress and anxiety levels in this cohort by  
226 calculating Spearman rank correlations between each measure (Fig 2). PCL-5, GAD-7, and PHQ-9  
227 scores were all mutually associated. Symptom Score was positively associated with PCL-5 ( $r = 0.25, p <$   
228  $0.05$ ), GAD-7 ( $r = 0.29, p < 0.05$ ), and PHQ-9 ( $r = 0.25, p < 0.05$ ) scores. Thus, the more complex Long  
229 COVID symptomatology, the worse stress, anxiety and depression symptoms a patient reported.

230 We refined this analysis to examine how each of the 20 items of the PCL-5 correlated with individual Long  
231 COVID symptoms that comprise the Symptom Score (Fig 3). Nearly all items on the PCL-5 were  
232 positively and significantly correlated with insomnia or sleep disturbance (17/20 items,  $p < 0.05$ ).  
233 Importantly, individual item correlations do not vary by PTSD Symptom Cluster (B, C, D, E) as identified in  
234 the DSM-5. Headache (11/20 items,  $p < 0.05$ ) and subjective cognitive impairment (9/20,  $p < 0.05$ ) were  
235 also significantly positively correlated with many items. Of note, whether the patient was currently  
236

237 exercising at time of assessment was negatively correlated with 5 items ( $p < 0.05$ ). The item most  
238 positively correlated with the greatest number of symptoms was item 8 ( $p < 0.05$ ): “In the past month, how  
239 much were you bothered by: Trouble remembering important parts of the stressful experience?”

240  
241 *Pharmacotherapy may moderate stress and anxiety-related Long COVID symptoms*  
242 We sought to determine if any ongoing pharmacotherapy with Long COVID symptoms could explain the  
243 presence of stress and anxiety symptoms in our cohort. To this end, we correlated GAD-7 and PCL-5  
244 scores with classes of medications reported taking at the time of Long COVID evaluation. Of note, 41% of  
245 patients take medications related to respiratory care well after initial COVID-19 infection (Table S1).  
246 Although PCL-5 and GAD-7 scores were positively and significantly correlated with mood stabilizers and  
247 stimulant prescriptions (Fig 4), Long COVID patients taking either class of medication had significantly  
248 higher GAD-7 scores compared to those not taking them ( $p = 0.031$  and  $0.035$ , respectively; Table 3),  
249 without significant differences in PCL-5 scores.  
250

251 **Discussion**

252 Despite the best efforts of public health and medical systems, the COVID-19 pandemic remains a burden  
253 in much of the world, underscoring the need for further research into both the impact of acute infection  
254 and its associated infection-associated chronic condition, known as Long COVID(2–5). SARS-CoV-2, the  
255 virus that causes COVID-19 and thus Long COVID, is neurotropic(20–23) and thus propagates  
256 throughout the central nervous system. The symptom clusters experienced by both acute COVID-19 and  
257 Long COVID patients imply significant distortions to normal functioning of nervous system.  
258 We hypothesized that chronic stress and mood disorders may significantly contribute to the complexity of  
259 Long COVID symptomatology, playing a key role in the abnormal neuro pathophysiology associated with  
260 the condition. To underscore the population affected, we emphasize the unique composition of our  
261 analytical sample, which is predominantly female (71%), Hispanic (53%), and obese (median BMI = 30).  
262 This highlights the relative share of Long COVID patients presenting for treatment in this region and  
263 emphasizes the high disease burden faced by this population. In this study, we present key findings and  
264 acknowledge limitations, aiming to encourage others to build on this work to elucidate the underlying  
265 mechanisms of Long COVID and drive the development of effective therapies and interventions.

266  
267 *Symptom Score is an effective clinical tool for Long COVID evaluation and longitudinal tracking*

268 We characterized Long COVID symptoms in a cohort of patients who, due to the unique nature of our  
269 study site in South Texas, represented categories of patients thought to be a greatest risk(4,14,15,18) for  
270 severe COVID-19 infection and thus Long COVID (N = 162; 71% female, 53% Hispanic, median BMI =  
271 30). We used the Symptom Score to correlate burden and complexity of multisystemic Long COVID  
272 symptomatology, which demonstrated clustering of symptoms that is highly consistent with larger and  
273 more detailed inventories of Long COVID symptoms from previous studies.

274 Our findings align with those of large cohort studies(9,11,12) and reveal a high burden of fatigue,  
275 cognitive impairment, and anxiety among Long COVID patients, exacerbating the core Long COVID  
276 symptom profile. The significant impact on quality of life and the increased risk of worsening psychiatric  
277 disorders in Long COVID(24,25) underscore the need for greater attention to neuropsychiatric symptoms  
278 in the management of Long COVID. Thus, we advance the Long COVID Symptom Score as an effective  
279 inventory or core symptoms across several major systems (e.g., cognitive, respiratory, neuropsychiatric,  
280 pain, and constitutive/gastrointestinal symptoms) for use in clinical settings that benefit from rapid  
281 screening tools. The Symptom Score may also assist with triaging patients for additional tests to detect  
282 neurovascular changes(26), neuroinflammation(27,28), and structural alterations(29–31) in patients with  
283 Long COVID.

284  
285 *Psychiatric comorbidity is more predictive of Long COVID severity than patient factors*

286 We found that comorbid stress and anxiety symptomatology as measured by PCL-5 and GAD-7  
287 inventories was more predictive of Long COVID symptomatology than any patient factor considered in  
288 this study. Nonetheless, it is difficult to attribute stress, anxiety, or satisfaction with life measures  
289 specifically to COVID-19 infection or chronic Long COVID symptomatology without knowledge of any  
290 index or inciting traumatic events. We also identified patients with premorbid anxiety disorders, who were  
291 not excluded from this study based on the original criteria, that may serve as a refined subgroup for future  
292 analyses on changes in anxiety levels attributable to neuropsychiatric burden in Long COVID. We  
293 anticipate this may be a difficult confounding factor to address, given the general stress and anxiety levels  
294 induced by the global COVID-19 pandemic at the time of study recruitment.

295 Future studies should include validated screening tools to enable quantification and thus more objective  
296 assessment of neuropsychiatric burden in Long COVID patients. This may aid the tracking of symptom  
297 progression over time. One gap in this study was access to an inventory to characterize symptoms  
298 related to the patient-reported cognitive impairment reported by 73% of our cohort at time of assessment.  
299 A standardized tool to assess specific features of cognitive impairments in this and other populations  
300 could point to underlying neurobiological pathways or circuitry that is particularly vulnerable to COVID-19  
301 infection or chronic damage related to Long COVID.

302  
303 *Some study interpretations limited due to study setting*

304 The results of this study highlight considerations of stress and anxiety in Long COVID patients.  
305 Importantly, we cannot rule out the impact of greater socioeconomic stressors experienced by historically  
306 marginalized groups on Long COVID Symptom Score, nor any measure of stress and anxiety used here.



307 Our results reflect patient status captured within a single visit to a Rehabilitation Medicine clinic and thus  
308 would likely benefit from long-term follow-up with increased sample size.  
309

## 310 311 **Materials and Methods**

312 This study was conducted under the approval of the Office of the Institutional Review Board at the  
313 University of Texas Health Science Center at San Antonio Long School of Medicine (protocol  
314 #20210194EX). Participants in this retrospective cohort study were men and women who were evaluated  
315 in a Rehabilitation Medicine outpatient clinic in South Texas from January 2020 to July 2021.  
316 The study setting was an outpatient psychiatry clinic in which each participant was evaluated, in a private  
317 room, by clinicians for Long COVID symptomatology and administered screening tools for stress, anxiety,  
318 and quality of life measures. The data was retrospectively collected directly from the medical chart in the  
319 University of Texas at San Antonio Health Science Center's Electronic Medical Record (EPIC).  
320 Responses were recorded directly into RedCap and then aggregated in a de-identified database for  
321 statistical analysis.  
322

### 323 *Analytical Population*

324 Eligible participants included patients over the age of 18 years old with a history of acute COVID-19  
325 infection confirmed either by positive COVID-19 test (89%) or evaluation by a clinician for COVID-19  
326 symptoms. Patients were seen at varying periods post-COVID-19 infection. Participants were ineligible if  
327 they were younger than 18 years old, did not have a history of acute COVID-19 infection, were evaluated  
328 for conditions apart from Long COVID, or were unable to read or speak in English to complete screening  
329 tools and clinical evaluation.

330 During the study period, 235 patients were clinically evaluated. In our analysis, we excluded patients who  
331 either did not complete the PTSD Checklist-Civilian Version 5 (PCL-5), Generalized Anxiety Disorder  
332 Scale 7 (GAD-7), or Satisfaction with Life Scale (SWLS). Patients were not excluded from analysis if they  
333 were missing information on other patient factors or screening tools. We excluded these individuals from  
334 some sub-analyses ("Missing"), as noted throughout this report. The final analytical sample included 162  
335 patients. These screening tools are outlined in detail below.  
336

### 337 *Patient Factors*

338 In addition to the above outlined measures, we also collected patient factors for use as covariates in this  
339 study (Table 1). Patient factors included biological sex, ethnicity/race, age, education level, body mass  
340 index (BMI), pre-existing psychiatric disorders, current medication list, type of health care institution,  
341 region, and employment status.  
342

### 343 *Long COVID Symptom Score*

344 We collected self-reported Long COVID symptomatology noted in the medical record from a single clinical  
345 evaluation of Long COVID symptoms(9,11) from all participants. Long COVID symptoms included: (1)  
346 positive COVID-19 test at the time of primary infection, (2) fatigue, (3) coughing or shortness of breath  
347 (SOB), (4) muscle or joint ache, (5) headache, (6) increased time spent in bed, (7) fever, (8) loss of smell,  
348 (9) loss of taste, (10) cognitive impairment, (11) insomnia or sleep disturbance, (12) weight loss, (13)  
349 diarrhea, (14) nausea or vomiting, (15) rash, (16) currently exercising. For our analysis, we then  
350 operationalized Long COVID symptoms and calculated a Symptom Score based on the total number of  
351 symptoms reported during clinical evaluation. We also evaluated factors thought to affect PASC symptom  
352 severity, such as the amount of elapsed time from Long COVID evaluation to initial acute COVID-19  
353 infection, whether the patient was hospitalized, required ventilation or supplemental oxygen, or  
354 experienced cardiac damage because of primary infection.  
355

### 356 *Stress and Posttraumatic Stress Disorder (PTSD) Assessment (PCL-5)*

357 Posttraumatic stress disorder (PTSD) Check List for DSM-5 (PCL-5(32,33)) was used to assess stress  
358 and trauma-related symptoms. The PCL-5 was adapted for the Diagnostic and Statistical Manual of  
359 Mental Disorders- Fifth Edition (DSM-5) and demonstrated strong reliability and validity(34). The PCL-5 is  
360 a 20-item inventory designed to gauge symptoms based on 4 major PTSD symptom clusters: Cluster B  
361 (The traumatic event is persistently experienced), Cluster C (Avoidance of trauma-related stimuli after  
362 trauma), Cluster D (Negative thoughts or feelings began or worsened after the trauma), Cluster E (Trauma-

363 related arousal and reactivity that began or worsened after the trauma. Participants rated the degree to  
364 which they experienced each symptom on a scale ranging from 1 (not at all) to 5 (extremely), with  
365 possible scores ranging from 17 to 85. Cut scores range from 30 to 60 depending on the variation and  
366 base rate of the disorder in the population and settings, and it is recommended to use higher cut-offs in  
367 populations with higher base rates, such as veterans, and lower cut scores with populations of lower base  
368 rates of PTSD(35). A total score of 31-33 suggests a diagnosis of PTSD and that the patient may benefit  
369 from PTSD treatment.

#### 370 371 *Anxiety Assessment (GAD-7)*

372 We used the Generalized Anxiety Disorder-7 (GAD-7(36)) to evaluate patients for presence and severity  
373 of anxiety. The GAD-7 is a self-report seven item questionnaire assessing symptoms of generalized  
374 anxiety disorder that has been found to have validity as a measure of anxiety in the general  
375 population(37). In this study, the GAD-7 was altered to reflect symptomatology within the time frame of  
376 the past month to match the frame of reference for other screening tools used in this study. GAD-7 scores  
377 were used to assign patients into standard categories based on anxiety-related symptoms: 0-4 = minimal  
378 anxiety, 5-9 = mild anxiety, 10-14 = moderate anxiety, 15-21 = severe anxiety.

#### 379 380 *Depression Assessment (PHQ-9)*

381 We used the 9-item Patient Health Questionnaire (PHQ-9(38)) to evaluate patients for presence and  
382 severity of depression. The PHQ-9 has a cut score of 6 that has been recommended for depression  
383 screening in primary care and a score of 10 or higher is used to detect symptoms of major depressive  
384 disorder(39).

#### 385 386 *Satisfaction with Life Assessment*

387 The Satisfaction with Life Scale (SWLS(40)) is a five item self-report Likert scale ("strongly disagree" to  
388 "strongly agree") to measure satisfaction with life as a proxy for subjective well-being. Past studies have  
389 established adequate reliability and predictive validity in a wide range of age groups(41). We analyzed  
390 patients who fell within the following categorical score ranges:

#### 391 392 *Statistical Analysis*

393 We used open-source statistical software (R version 4.3+, Vienna, Austria) to complete all statistical  
394 analyses in this study. Patient factors were tested for associations with Symptom Score by stratifying  
395 participants as above or below the median symptom score and using the Wilcoxon rank sum test  
396 (continuous variables) or Fisher's exact test (categorical variables). Medication use for each category was  
397 used as a predictor within linear regression models for each outcome (PCL-5, GAD-7, PHQ-9, and  
398 Symptom Score). Spearman's correlations were used to identify associations amongst these outcomes.  
399 All testing was two-sided ( $\alpha = 0.05$ ).

400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410

#### 411 **References**


- 412 1. WHO Director-General's opening remarks at the media briefing – 5 May 2023 [Internet]. [cited  
413 2024 Aug 1]. Available from: [https://www.who.int/director-general/speeches/detail/who-director-](https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing---5-may-2023)  
414 [general-s-opening-remarks-at-the-media-briefing---5-may-2023](https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing---5-may-2023)
- 415 2. Meyerowitz EA, Scott J, Richterman A, Male V, Cevik M. Clinical course and management of  
416 COVID-19 in the era of widespread population immunity. *Nature Reviews Microbiology* 2023 22:2  
417 [Internet]. 2023 Dec 19 [cited 2024 Aug 1];22(2):75–88. Available from:  
418 <https://www.nature.com/articles/s41579-023-01001-1>

- 419 3. Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, Evaluation, and Treatment  
420 of Coronavirus (COVID-19). StatPearls [Internet]. 2023 Aug 18 [cited 2024 Aug 1]; Available from:  
421 <https://www.ncbi.nlm.nih.gov/books/NBK554776/>
- 422 4. Groff D, Sun A, Ssentongo AE, Ba DM, Parsons N, Poudel GR, et al. Short-term and Long-term  
423 Rates of Postacute Sequelae of SARS-CoV-2 Infection: A Systematic Review. JAMA Netw Open  
424 [Internet]. 2021 Oct 1 [cited 2024 Aug 1];4(10):e2128568–e2128568. Available from:  
425 <https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2784918>
- 426 5. Thaweethai T, Jolley SE, Karlson EW, Levitan EB, Levy B, McComsey GA, et al. Development of  
427 a Definition of Postacute Sequelae of SARS-CoV-2 Infection. JAMA [Internet]. 2023 Jun 13 [cited  
428 2024 Aug 1];329(22):1934–46. Available from:  
429 <https://jamanetwork.com/journals/jama/fullarticle/2805540>
- 430 6. National Academies of Sciences E and M. A Long COVID Definition: A Chronic, Systemic Disease  
431 State with Profound Consequences. A Long COVID Definition. 2024 Jun 11;
- 432 7. Reese JT, Blau H, Casiraghi E, Bergquist T, Looma JJ, Callahan TJ, et al. Generalisable long  
433 COVID subtypes: Findings from the NIH N3C and RECOVER programmes. EBioMedicine  
434 [Internet]. 2023 Jan 1 [cited 2024 Aug 1];87:104413. Available from: [/pmc/articles/PMC9769411/](https://pmc/articles/PMC9769411/)
- 435 8. Danesh V, Arroliga AC, Bourgeois JA, Boehm LM, McNeal MJ, Widmer AJ, et al. Symptom  
436 Clusters Seen in Adult COVID-19 Recovery Clinic Care Seekers. J Gen Intern Med [Internet].  
437 2023 Feb 1 [cited 2024 Aug 1];38(2):442. Available from: [/pmc/articles/PMC9663188/](https://pmc/articles/PMC9663188/)
- 438 9. Cai M, Xie Y, Topol EJ, Al-Aly Z. Three-year outcomes of post-acute sequelae of COVID-19.  
439 Nature Medicine 2024 30:6 [Internet]. 2024 May 30 [cited 2024 Aug 1];30(6):1564–73. Available  
440 from: <https://www.nature.com/articles/s41591-024-02987-8>
- 441 10. Bell ML, Catalfamo CJ, Farland L V., Ernst KC, Jacobs ET, Klimentidis YC, et al. Post-acute  
442 sequelae of COVID-19 in a non-hospitalized cohort: Results from the Arizona CoVHORT. PLoS  
443 One [Internet]. 2021 Aug 1 [cited 2024 Aug 1];16(8):e0254347. Available from:  
444 <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0254347>
- 445 11. Bowe B, Xie Y, Al-Aly Z. Postacute sequelae of COVID-19 at 2 years. Nature Medicine 2023 29:9  
446 [Internet]. 2023 Aug 21 [cited 2024 Aug 1];29(9):2347–57. Available from:  
447 <https://www.nature.com/articles/s41591-023-02521-2>
- 448 12. Peter RS, Nieters A, Kräusslich HG, Brockmann SO, Göpel S, Kindle G, et al. Post-acute  
449 sequelae of covid-19 six to 12 months after infection: population based study. BMJ [Internet]. 2022  
450 Oct 13 [cited 2024 Aug 1];379. Available from: <https://www.bmj.com/content/379/bmj-2022-071050>
- 451 13. Cutler DM. The Costs of Long COVID. JAMA Health Forum [Internet]. 2022 May 12 [cited 2024  
452 Aug 1];3(5). Available from: <https://pubmed.ncbi.nlm.nih.gov/36219031/>
- 453 14. Wang C, Ramasamy A, Verduzco-Gutierrez M, Brode WM, Melamed E. Acute and post-acute  
454 sequelae of SARS-CoV-2 infection: a review of risk factors and social determinants. Virol J  
455 [Internet]. 2023 Dec 1 [cited 2024 Aug 1];20(1):1–11. Available from:  
456 <https://virologyj.biomedcentral.com/articles/10.1186/s12985-023-02061-8>
- 457 15. Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and  
458 recommendations. Nat Rev Microbiol [Internet]. 2023 Mar 1 [cited 2024 Aug 1];21(3):133–46.  
459 Available from: <https://pubmed.ncbi.nlm.nih.gov/36639608/>
- 460 16. Estrada L V., Levasseur JL, Maxim A, Benavidez GA, Porter KMP. Structural Racism, Place, and  
461 COVID-19: A Narrative Review Describing How We Prepare for an Endemic COVID-19 Future.  
462 Health Equity [Internet]. 2022 May 1 [cited 2024 Aug 1];6(1):356. Available from:  
463 [/pmc/articles/PMC9148659/](https://pmc/articles/PMC9148659/)
- 464 17. Kantamneni N. The impact of the COVID-19 pandemic on marginalized populations in the United  
465 States: A research agenda. J Vocat Behav [Internet]. 2020 Jun 1 [cited 2024 Aug 1];119:103439.  
466 Available from: [/pmc/articles/PMC7205696/](https://pmc/articles/PMC7205696/)
- 467 18. Munipalli B, Ma Y, Li Z, Ganesh R, Knight D, Logvinov II, et al. Risk factors for post-acute  
468 sequelae of COVID-19: Survey results from a tertiary care hospital.  
469 <https://doi.org/10.1177/10815589231190560> [Internet]. 2023 Aug 12 [cited 2024 Aug 1];71(8):896–  
470 906. Available from: <https://journals.sagepub.com/doi/abs/10.1177/10815589231190560>
- 471 19. Hu W, Tang R, Gong S, Liu J, Li J, Liao C. The Prevalence and Associated Factors of Post-  
472 COVID-19 Fatigue: A Systematic Review and Meta-Analysis. Cureus [Internet]. 2024 Jul 2 [cited  
473 2024 Aug 1];16(7). Available from: <https://pubmed.ncbi.nlm.nih.gov/39092372/>


- 474 20. Roy D, Ghosh R, Dubey S, Dubey MJ, Benito-Leon J, Kanti Ray B. Neurological and  
475 Neuropsychiatric Impacts of COVID-19 Pandemic. *Can J Neurol Sci* [Internet]. 2021 Jan 1 [cited  
476 2024 Aug 21];48(1):9–24. Available from: <https://pubmed.ncbi.nlm.nih.gov/32753076/>
- 477 21. Song WJ, Hui CKM, Hull JH, Birring SS, McGarvey L, Mazzone SB, et al. Confronting COVID-19-  
478 associated cough and the post-COVID syndrome: role of viral neurotropism, neuroinflammation,  
479 and neuroimmune responses. *Lancet Respir Med* [Internet]. 2021 May 1 [cited 2024 Aug  
480 21];9(5):533–44. Available from: <https://pubmed.ncbi.nlm.nih.gov/33857435/>
- 481 22. Sarubbo F, El Haji K, Vidal-Balle A, Bargay Lleonart J. Neurological consequences of COVID-19  
482 and brain related pathogenic mechanisms: A new challenge for neuroscience. *Brain Behav Immun*  
483 *Health* [Internet]. 2022 Feb 1 [cited 2024 Aug 21];19. Available from: [/pmc/articles/PMC8629776/](https://pubmed.ncbi.nlm.nih.gov/3629776/)
- 484 23. Singh D, Singh E. An overview of the neurological aspects in COVID-19 infection. *J Chem*  
485 *Neuroanat* [Internet]. 2022 Jul 1 [cited 2024 Aug 21];122:102101. Available from:  
486 [/pmc/articles/PMC9008979/](https://pubmed.ncbi.nlm.nih.gov/3629776/)
- 487 24. Coleman B, Casiraghi E, Callahan TJ, Blau H, Chan LE, Laraway B, et al. Association of post-  
488 COVID phenotypic manifestations with new-onset psychiatric disease. *Translational Psychiatry*  
489 2024 14:1 [Internet]. 2024 Jun 8 [cited 2024 Aug 1];14(1):1–9. Available from:  
490 <https://www.nature.com/articles/s41398-024-02967-z>
- 491 25. Paez AF, Nicolalde B, Esquetini-Vernon C, Lara-Taranchenko Y, Zambrano K, Ocampo J, et al.  
492 Psychiatric disorders in Post-acute COVID-syndrome (PDPACS): Recommendations for health  
493 care professionals. *European Neuropsychopharmacology* [Internet]. 2022 May 1 [cited 2024 Aug  
494 1];58:100. Available from: [/pmc/articles/PMC8956896/](https://pubmed.ncbi.nlm.nih.gov/3629776/)
- 495 26. Ajčević M, Iscra K, Furlanis G, Michelutti M, Miladinović A, Buoite Stella A, et al. Cerebral  
496 hypoperfusion in post-COVID-19 cognitively impaired subjects revealed by arterial spin labeling  
497 MRI. *Scientific Reports* 2023 13:1 [Internet]. 2023 Apr 10 [cited 2024 Aug 21];13(1):1–9. Available  
498 from: <https://www.nature.com/articles/s41598-023-32275-3>
- 499 27. Braga J, Lepra M, Kish SJ, Rusjan PM, Nasser Z, Verhoeff N, et al. Neuroinflammation After  
500 COVID-19 With Persistent Depressive and Cognitive Symptoms. *JAMA Psychiatry* [Internet]. 2023  
501 Aug 1 [cited 2024 Aug 21];80(8):787–95. Available from:  
502 <https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2805366>
- 503 28. VanElzakker MB, Bues HF, Brusafferri L, Kim M, Saadi D, Ratai EM, et al. Neuroinflammation in  
504 post-acute sequelae of COVID-19 (PASC) as assessed by [11C]PBR28 PET correlates with  
505 vascular disease measures. *Brain Behav Immun* [Internet]. 2024 Jul 1 [cited 2024 Aug  
506 21];119:713. Available from: [/pmc/articles/PMC11225883/](https://pubmed.ncbi.nlm.nih.gov/3629776/)
- 507 29. Cecchetti G, Agosta F, Canu E, Basaia S, Barbieri A, Cardamone R, et al. Cognitive, EEG, and  
508 MRI features of COVID-19 survivors: a 10-month study. *J Neurol* [Internet]. 2022 Jul 1 [cited 2024  
509 Aug 21];269(7):3400–12. Available from: <https://pubmed.ncbi.nlm.nih.gov/35249144/>
- 510 30. Chen B, Chen C, Zheng J, Li R, Xu J. Insights Into Neuroimaging Findings of Patients With  
511 Coronavirus Disease 2019 Presenting With Neurological Manifestations. *Front Neurol* [Internet].  
512 2020 Nov 9 [cited 2024 Aug 21];11:593520. Available from: [/pmc/articles/PMC7680864/](https://pubmed.ncbi.nlm.nih.gov/3629776/)
- 513 31. Huang S, Zhou Z, Yang D, Zhao W, Zeng M, Xie X, et al. Persistent white matter changes in  
514 recovered COVID-19 patients at the 1-year follow-up. *Brain* [Internet]. 2022 Jun 3 [cited 2024 Aug  
515 21];145(5):1830–8. Available from: <https://dx.doi.org/10.1093/brain/awab435>
- 516 32. Weathers FW, LBT, KTM, PPA, MBP, & SPP. [www.ptsd.va.gov](https://www.ptsd.va.gov). 2013. The PTSD Checklist for  
517 DSM-5 (PCL-5).
- 518 33. Forkus SR, Raudales AM, Rafiuddin HS, Weiss NH, Messman BA, Contractor AA. The  
519 Posttraumatic Stress Disorder (PTSD) Checklist for DSM–5: A Systematic Review of Existing  
520 Psychometric Evidence. *Clin Psychol (New York)* [Internet]. 2023 Sep 8 [cited 2024 Aug  
521 1];30(1):110. Available from: [/pmc/articles/PMC10292741/](https://pubmed.ncbi.nlm.nih.gov/3629776/)
- 522 34. Blevins CA, Weathers FW, Davis MT, Witte TK, Domino JL. The Posttraumatic Stress Disorder  
523 Checklist for DSM-5 (PCL-5): Development and Initial Psychometric Evaluation. *J Trauma Stress*  
524 [Internet]. 2015 Dec 1 [cited 2024 Aug 1];28(6):489–98. Available from:  
525 <https://pubmed.ncbi.nlm.nih.gov/26606250/>
- 526 35. McDonald SD, Calhoun PS. The diagnostic accuracy of the PTSD checklist: a critical review. *Clin*  
527 *Psychol Rev* [Internet]. 2010 Dec [cited 2024 Aug 1];30(8):976–87. Available from:  
528 <https://pubmed.ncbi.nlm.nih.gov/20705376/>

- 529 36. Spitzer RL, Kroenke K, Williams JBW, Löwe B. A brief measure for assessing generalized anxiety  
530 disorder: the GAD-7. Arch Intern Med [Internet]. 2006 May 22 [cited 2024 Aug 1];166(10):1092–7.  
531 Available from: <https://pubmed.ncbi.nlm.nih.gov/16717171/>
- 532 37. Löwe B, Decker O, Müller S, Brähler E, Schellberg D, Herzog W, et al. Validation and  
533 standardization of the Generalized Anxiety Disorder Screener (GAD-7) in the general population.  
534 Med Care [Internet]. 2008 Feb [cited 2024 Aug 1];46(3):266–74. Available from:  
535 <https://pubmed.ncbi.nlm.nih.gov/18388841/>
- 536 38. Spitzer RL, Kroenke K, Williams JBW. Validation and utility of a self-report version of PRIME-MD:  
537 the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health  
538 Questionnaire. JAMA [Internet]. 1999 Nov 10 [cited 2024 Aug 21];282(18):1737–44. Available  
539 from: <https://pubmed.ncbi.nlm.nih.gov/10568646/>
- 540 39. Arroll B, Goodyear-Smith F, Crengle S, Gunn J, Kerse N, Fishman T, et al. Validation of PHQ-2  
541 and PHQ-9 to screen for major depression in the primary care population. Ann Fam Med [Internet].  
542 2010 [cited 2024 Aug 21];8(4):348–53. Available from: <https://pubmed.ncbi.nlm.nih.gov/20644190/>
- 543 40. Diener E, Emmons RA, Larsen RJ, Griffin S. The Satisfaction With Life Scale. J Pers Assess  
544 [Internet]. 1985 Feb 1 [cited 2024 Aug 1];49(1):71–5. Available from:  
545 <https://pubmed.ncbi.nlm.nih.gov/16367493/>
- 546 41. Pavot W, Diener E, Colvin CR, Sandvik E. Further validation of the Satisfaction with Life Scale:  
547 evidence for the cross-method convergence of well-being measures. J Pers Assess [Internet].  
548 1991 [cited 2024 Aug 1];57(1):149–61. Available from: <https://pubmed.ncbi.nlm.nih.gov/1920028/>
- 549  
550  
551

552 **Figures**  
553




554  
555  
556  
557 **Figure 1. Summary of Symptom Score Components and incidence (%) in analytical sample.** We  
558 collected self-reported data on PASC symptomatology across all major systems as previously described  
559 (Bowe et al 2023; Cai et al 2024). Symptoms were ranked by incidence (% of patients who reported  
560 symptom) in our sample. We then calculated a PASC Symptom Score based on the total number of  
561 comorbid symptoms present in a patient based on the top 16 most common symptoms, summarized here.  
562 Of note, the most common PASC symptoms noted by our sample was fatigue (93%). There was a high  
563 burden of symptoms classically related to acute COVID-19 infection (coughing, shortness of breath [SOB],  
564 loss of smell and taste) as well as subjective neuropsychiatric symptoms (cognitive impairment = 79%,  
565 muscle/joint pain = 78%, insomnia/sleep disturbance = 58%).



566  
567  
568  
569  
570  
571  
572  
573  
574  
575


**Figure 2. Correlation of Symptom Score with measures of depression (PHQ-9), stress (PCL-5), and anxiety (GAD-7) symptoms.** We assessed whether PASC Symptom Scores were correlated with the presence of depression, stress, or anxiety symptomatology as determined by validated screening tools. Spearman rank correlations were computed for each pairwise combination of PASC Symptom Score and PCL-5 or GAD-7 scores. PHQ-9, PCL-5, and GAD-7 scores were mutually associated. PASC Symptom Score was positively associated with PHQ-9 (0.218,  $p < 0.05$ ), GAD-7 ( $r = 0.29$ ,  $p < 0.05$ ) and PCL-5 ( $r = 0.25$ ,  $p < 0.05$ ).



576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590

**Figure 3. Correlation of individual PCL-5 items with Long COVID Symptoms.** Spearman rank correlations were calculated for the intersection of the score of each item, reflecting frequency of stress and PTSD-related symptoms by item of the PCL-5 and the PASC symptoms used to calculate PASC Symptom Score. We contextualize the PCL-5 item scores with their respective symptom clusters for Post-Traumatic Stress Disorder according to the DSM-5, designated to the left of each PCL-5 item: Cluster B (The traumatic event is persistently experienced), Cluster C (Avoidance of trauma-related stimuli after trauma), Cluster D (Negative thoughts or feelings began or worsened after the trauma), Cluster E (Trauma-related arousal and reactivity that began or worsened after the trauma). Correlations are given for all findings with  $p < 0.05$ .





591  
592  
593  
594  
595  
596  
597  
598

**Figure 4. Correlation of depression (PHQ-9), anxiety (GAD-7), and stress (PCL-5) symptomatology with current medications.** Spearman rank correlations were calculated for the intersection of PHQ-9, GAD-7, and PCL-5 total scores with classes of current medications endorsed by self-report. Correlations are given for all findings with  $p < 0.05$ .

599  
600  
601

**Tables**

**Table 1. Summary of patient factors and prediction of Long COVID Symptom Score.**

Patient Factor	PASC Symptom Score			p-value <sup>2</sup>
	Overall, N = 162 <sup>1</sup>	> Median, N = 78 <sup>1</sup>	≤ Median, N = 84 <sup>1</sup>	
Symptom Score	9 (8, 11)	11 (10, 12)	8 (6, 8)	<0.001
Sex				0.2
Female	117 (73%)	60 (78%)	57 (68%)	
Male	44 (27%)	17 (22%)	27 (32%)	
(Missing)	1	1	0	
Age at Evaluation	44 (35, 54)	44 (36, 52)	46 (34, 56)	0.4
BMI	30 (26, 36)	30 (26, 35)	29 (26, 36)	0.7
(Missing)	22	12	10	
Race/Ethnicity <sup>3</sup>				0.8
Black or African American	6 (3.9%)	4 (5.3%)	2 (2.6%)	
White	61 (40%)	29 (39%)	32 (42%)	
Hispanic	78 (51%)	38 (51%)	40 (52%)	
Other	7 (4.6%)	4 (5.3%)	3 (3.9%)	
(Missing)	10	3	7	
Time since infection (Days)	190 (83, 278)	218 (83, 295)	169 (95, 264)	0.4
(Missing)	5	0	5	
Time since infection < 30 Days	8 (5.1%)	1 (1.3%)	7 (8.9%)	0.063
(Missing)	5	0	5	

<sup>1</sup> Median (IQR); N (%)

<sup>2</sup> Wilcoxon rank sum test; Pearson's Chi-squared test; Fisher's exact test (categorical variables)

<sup>3</sup> Other includes: American Indian Alaska Native, Asian. Unknown set to Missing

602  
603

604 **Table 2. Categorical score results of screening tools for stress (PCL-5), anxiety (GAD-7), and**  
605 **depression (PHQ-9) symptoms, and satisfaction with life (SWL) in Long COVID patients.**

<b>PCL-5 Score (N = 162)</b>	<b>N (%)</b>
Not elevated	90 (56%)
Significantly elevated trauma symptoms of PTSD	72 (44%)
<b>GAD-7 Score (N = 143)</b>	<b>N (%)</b>
No Significant Symptoms	44 (31%)
Mild	38 (27%)
Moderate	35 (24%)
Severe	26 (18%)
(Missing)	19
<b>PHQ-9 Score (N = 146)</b>	<b>N (%)</b>
Minimal Depression	38 (26%)
Mild Depression	32 (22%)
Moderate Depression	34 (23%)
Moderately Severe Depression	21 (14%)
Severe Depression	21 (14%)
(Missing)	16
<b>SWL Score (N = 147)</b>	<b>N (%)</b>
Dissatisfied	11 (7.5%)
Extremely dissatisfied	14 (9.5%)
Extremely satisfied	18 (12%)
Neutral	4 (2.7%)
Satisfied	39 (27%)
Slightly dissatisfied	35 (24%)
Slightly satisfied	26 (18%)
(Missing)	15

606  
607  
608  
609

610 **Table 3. Correlation of anxiety, stress, and depression symptomatology with mood stabilizer and**  
 611 **stimulant class medications.**

<b>Mood Stabilizer Class</b>					
<b>Characteristic</b>	<b>Yes, N = 6<sup>1</sup></b>	<b>No, N = 156<sup>1</sup></b>	<b>Difference<sup>2</sup></b>	<b>95% CI<sup>2,3</sup></b>	<b>p-value<sup>2</sup></b>
GAD-7 Score	15.8 (6.3)	8.2 (6.0)	7.6	1.0, 14	0.031
(Missing)	0	19			
PCL-5 Score	54 (23)	30 (21)	24	-0.49, 48	0.053
PHQ-9 Score	18 (7)	10 (7)	7.9	0.89, 15	0.034
(Missing)	0	16			
<b>Stimulant Class</b>					
<b>Characteristic</b>	<b>Yes, N = 8<sup>1</sup></b>	<b>No, N = 154<sup>1</sup></b>	<b>Difference<sup>2</sup></b>	<b>95% CI<sup>2,3</sup></b>	<b>p-value<sup>2</sup></b>
GAD-7 Score	13.1 (4.7)	8.3 (6.1)	4.9	0.46, 9.3	0.035
(Missing)	1	18			
PCL-5 Score	48 (23)	30 (21)	18	-1.7, 37	0.068
PHQ-9 Score	17 (5)	10 (7)	7.1	2.4, 12	0.009
(Missing)	1	15			

<sup>1</sup> Mean (SD)

<sup>2</sup> Welch Two Sample t-test

<sup>3</sup> CI = Confidence Interval

612